View Future GrowthLadRx 過去の業績過去 基準チェック /06LadRxの収益は年平均-250.2%で減少しているが、Biotechs業界はgrowingで36.2%年平均の収益となった。主要情報-250.19%収益成長率-250.76%EPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報31 Mar 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 16LadRx Corporation Announces Resignation of Joel Caldwell from the Board of Directors and All Board Committees, Effective as of April 15, 2025LadRx Corporation announced on April 14, 2025, Joel Caldwell tendered his resignation from the board of directors of the company and all Board committees thereto, effective as of April 15, 2025. Mr. Caldwell’s resignation was not in connection with any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.お知らせ • Aug 21LadRx Corporation, Annual General Meeting, Oct 04, 2024LadRx Corporation, Annual General Meeting, Oct 04, 2024. Location: 11726 san vicente blvd, suite 650, ca 90049, los angeles United Statesお知らせ • Jul 29LadRx Corporation, Annual General Meeting, Sep 06, 2023LadRx Corporation, Annual General Meeting, Sep 06, 2023, at 10:00 Pacific Daylight. Location: 11726 San Vicente Boulevard, Suite 650, Los Angeles California United States Agenda: To consider the election of one Class II director to serve until the 2026 Annual Meeting of Stockholders; to consider the approval to amend the Company’s governing documents (Restated Certificate of Incorporation and By-Laws) to declassify the structure of the Board, such that each director standing for election shall only be eligible to be elected for one-year terms; to consider the ratification of the appointment of Weinberg & Company as company's independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider the approval, on an advisory basis, the compensation of company's named executive officers as disclosed in this Proxy Statement; to consider the approval, on an advisory, basis, regarding the frequency of future stockholder advisory votes to approve the compensation of company's named executive officers; and to consider other matters.お知らせ • Oct 08CytRx Corporation Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’S Pancreatic CancerCytRx Corporation announced that it has highlighted the use of its licensed drug – aldoxorubicin – in the combination immunotherapy used by ImmunityBio Inc. and NantKwest Inc. to treat former Senate Majority Leader Harry Reid’s stage IV pancreatic cancer. It was widely reported in June 2020 that former Senator Reid described himself as being in “complete remission” after receiving experimental treatment pioneered by the Chief Executive Officer of ImmunityBio and NantKwest.お知らせ • Sep 30Cytrx Corporation, Advanced Bioscience Laboratories and University of Massachusetts Announce First Patients Enrolled in Hiv Vaccine TrialCytRx Corp. Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) announced that investigators have enrolled and inoculated the first patients in the Phase I trial for an experimental HIV vaccine developed by the University of Massachusetts Medical School and ABL and supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The clinical trial, whose primary objective is to determine the safety and tolerability of the multiple dosing levels of the polyvalent vaccine. The trial will enroll 36 people who do not have HIV. The vaccine contains only portions of the HIV genome and, therefore, individuals receiving inoculations cannot get HIV from the vaccine. Volunteers' given the DNA and protein boost vaccine, will be carefully monitored for any adverse effects, and will also have samples collected in order to measure immune responses over time.お知らせ • Sep 18CytRx Corporation Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type CCytRx Corporation highlighted that Orphayzme A/S (“Orphazyme”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted, with Priority Review, the company’s New Drug Application (“NDA”) for arimoclomol for the treatment of Niemann-Pick disease Type C (“NPC”). The FDA grants Priority Review to applications for potential therapies that, if approved, could offer a significant improvement in safety, effectiveness, diagnosis or prevention of serious conditions. This designation shortens the review period from the standard 10 months to 6 months from the acceptance of the NDA. The FDA has set a target action date of March 17, 2021 under the Prescription Drug User Fee Act (“PDUFA”) and has indicated that it does not currently plan to hold an advisory committee meeting to discuss the application. Arimoclomol was previously granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file a Marketing Authorisation Application with the European Medicines Agency for arimoclomol in NPC in H2 2020.収支内訳LadRx の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:LADX 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 250-23131 Dec 240-23130 Sep 240-33130 Jun 240-33131 Mar 24023031 Dec 23004030 Sep 23007030 Jun 23004031 Mar 230-44031 Dec 220-55030 Sep 220-132030 Jun 220-136031 Mar 220-146031 Dec 210-136030 Sep 210-65030 Jun 210-76131 Mar 210-76131 Dec 200-76130 Sep 200-87130 Jun 200-77031 Mar 200-77031 Dec 190-87030 Sep 190-66030 Jun 190-77031 Mar 190-77031 Dec 180-98030 Sep 180-89-130 Jun 180-1011431 Mar 180-23121031 Dec 170-30131630 Sep 170-38152430 Jun 170-45142831 Mar 170-49153531 Dec 160-51163630 Sep 160-65164230 Jun 160-60154131 Mar 160-54153931 Dec 150-59144330 Sep 150-50144030 Jun 150-481442質の高い収益: LADXは現在利益が出ていません。利益率の向上: LADXは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: LADXの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: LADXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: LADXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 54.5% ) と比較することは困難です。株主資本利益率高いROE: LADXの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 04:48終値2026/06/03 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋LadRx Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Ashok KumarAegis Capital CorporationMorris AjzenmanGriffin SecuritiesAndrew FeinH.C. Wainwright & Co.5 その他のアナリストを表示
お知らせ • Apr 16LadRx Corporation Announces Resignation of Joel Caldwell from the Board of Directors and All Board Committees, Effective as of April 15, 2025LadRx Corporation announced on April 14, 2025, Joel Caldwell tendered his resignation from the board of directors of the company and all Board committees thereto, effective as of April 15, 2025. Mr. Caldwell’s resignation was not in connection with any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
お知らせ • Aug 21LadRx Corporation, Annual General Meeting, Oct 04, 2024LadRx Corporation, Annual General Meeting, Oct 04, 2024. Location: 11726 san vicente blvd, suite 650, ca 90049, los angeles United States
お知らせ • Jul 29LadRx Corporation, Annual General Meeting, Sep 06, 2023LadRx Corporation, Annual General Meeting, Sep 06, 2023, at 10:00 Pacific Daylight. Location: 11726 San Vicente Boulevard, Suite 650, Los Angeles California United States Agenda: To consider the election of one Class II director to serve until the 2026 Annual Meeting of Stockholders; to consider the approval to amend the Company’s governing documents (Restated Certificate of Incorporation and By-Laws) to declassify the structure of the Board, such that each director standing for election shall only be eligible to be elected for one-year terms; to consider the ratification of the appointment of Weinberg & Company as company's independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider the approval, on an advisory basis, the compensation of company's named executive officers as disclosed in this Proxy Statement; to consider the approval, on an advisory, basis, regarding the frequency of future stockholder advisory votes to approve the compensation of company's named executive officers; and to consider other matters.
お知らせ • Oct 08CytRx Corporation Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’S Pancreatic CancerCytRx Corporation announced that it has highlighted the use of its licensed drug – aldoxorubicin – in the combination immunotherapy used by ImmunityBio Inc. and NantKwest Inc. to treat former Senate Majority Leader Harry Reid’s stage IV pancreatic cancer. It was widely reported in June 2020 that former Senator Reid described himself as being in “complete remission” after receiving experimental treatment pioneered by the Chief Executive Officer of ImmunityBio and NantKwest.
お知らせ • Sep 30Cytrx Corporation, Advanced Bioscience Laboratories and University of Massachusetts Announce First Patients Enrolled in Hiv Vaccine TrialCytRx Corp. Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) announced that investigators have enrolled and inoculated the first patients in the Phase I trial for an experimental HIV vaccine developed by the University of Massachusetts Medical School and ABL and supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The clinical trial, whose primary objective is to determine the safety and tolerability of the multiple dosing levels of the polyvalent vaccine. The trial will enroll 36 people who do not have HIV. The vaccine contains only portions of the HIV genome and, therefore, individuals receiving inoculations cannot get HIV from the vaccine. Volunteers' given the DNA and protein boost vaccine, will be carefully monitored for any adverse effects, and will also have samples collected in order to measure immune responses over time.
お知らせ • Sep 18CytRx Corporation Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type CCytRx Corporation highlighted that Orphayzme A/S (“Orphazyme”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted, with Priority Review, the company’s New Drug Application (“NDA”) for arimoclomol for the treatment of Niemann-Pick disease Type C (“NPC”). The FDA grants Priority Review to applications for potential therapies that, if approved, could offer a significant improvement in safety, effectiveness, diagnosis or prevention of serious conditions. This designation shortens the review period from the standard 10 months to 6 months from the acceptance of the NDA. The FDA has set a target action date of March 17, 2021 under the Prescription Drug User Fee Act (“PDUFA”) and has indicated that it does not currently plan to hold an advisory committee meeting to discuss the application. Arimoclomol was previously granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file a Marketing Authorisation Application with the European Medicines Agency for arimoclomol in NPC in H2 2020.